A selection of awards recently earned by Dana-Farber and our staff
November - 2017
Dana-Farber Cancer Institute President and CEO, Laurie H. Glimcher, MD, was honored by the AAMC (Association of American Medical Colleges) with the prestigious Award for
Distinguished Research in the Biomedical Sciences at a special presentation during the AAMC annual meeting in Boston.
August – October 2017
Dana-Farber/New Hampshire Oncology-Hematology has been recognized with a gold award by the New Hampshire Union Leader’s
annual Readers’ Choice program. The satellite facility, based in Londonderry, N.H., was chosen for the highest award in the Cancer Care category by readers who voted online beginning last April.
Dana-Farber’s revamped Redstone Family Vivarium has won the Facility of the Year Award, a TurnKey Award from ALN Magazine, which reports on research facilities. A Vivarium management team was also the recipient of the Partners in Excellence Award for
Leadership and Innovation for incorporating energy saving features, development of electronic record applications, and providing systems that improve research functions.
Jacqueline S. Garcia, MD, has received a $600,000 translational research grant from the Leukemia & Lymphoma Society (LLS) through its Translational Research Program to support an investigator-initiated, Cancer Therapy Evaluation Program/Experimental Therapeutics Clinical Trials Network sponsored phase 1 study of a two-drug combination for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.
Lindsay Frazier, MD, is a co-leader of an international effort to improve care and outcomes for children with cancer in low- and middle-income countries. She was one of 45 experts from 16 countries who met in Toronto in early September to chart a course for convincing governments to scale up effective interventions for childhood cancer worldwide. The experts are working in groups to develop an investment case for funding management of childhood cancer as part of a Commission on Sustainable Pediatric Cancer Care to be launched by The Lancet Oncology journal in 2018.
Ann Partridge, MD, MPH, has received the 2016 Carol Friedman Award from the Centers for Disease Control’s (CDC) Division of Cancer Prevention and Control (DCPC). The prestigious award is given annually by the CDC to a “champion of comprehensive cancer control who has made a substantial commitment by including survivorship activities in cancer control planning.”
The Hope Funds for Cancer Research honored three outstanding individuals with its 2017 Award of Excellence in the areas of basic science, clinical development, and medicine at its annual awards dinner. This year's honoree for Medicine was George P. Canellos, MD, Institute Physician at Dana-Farber and Rosenberg Professor of Medicine at Harvard Medical School.
Robin Antonellis, vice president of Human Resources, was elected to the board of directors of the New England Employee Benefits Council, where she will serve a three-year term.
Benjamin Ebert, MD, PhD, was named the recipient of the 2017 William Dameshek Prize from the American Society of Hematology (ASH) for his seminal discoveries in multiple
areas of non-malignant and malignant hematology.
Glorian Sorensen, PhD, is the recipient of the 2017 Mark Dundon Research Award from the Health Enhancement Research Organization (HERO). Her selection recognizes research throughout
her career that advances the science of employee health and well-being.
The American Thyroid Association (ATA) has awarded research grants to Glenn J. Hanna, MD, and Jens Lohr, MD, PhD.
Both grants are funded by the Thyroid Cancer Survivors’ Association Inc. Hanna’s grant from the ATA supports his research whose aim is to discover predictors of response or resistance to immunotherapy treatment with checkpoint inhibitor drugs, which
have shown clinical benefit in a small number of patients with advanced thyroid tumors. Lohr, of Medical Oncology, will study whether testing a “liquid biopsy” from a vial of blood can effectively measure the response to treatment of a patient with
Wendy Gettleman, vice president of Facilities Management and Real Estate, was named one of the 15 Women of FIRE (Finance, Insurance, and Real Estate), by Banker & Tradesman.
Nikhil Wagle, MD, was designated for funding from the AVON 39 The Wall to End Breast Cancer. Wagle will receive $150,000 in 2017, with a possibility of an additional year of funding at the
same level in 2018 for his project to study the development of treatment resistance in estrogen receptor-expressing (ER+) metastatic breast cancer.
Seven Dana-Farber researchers in Pediatric Oncology – Pratiti Bandopadhayay, PhD, MBBS; Brian Crompton, MD;
Christine Duncan, MD; A. Lindsay Frazier, MD; Brenton Mar, MD, PhD;
Kimberly Stegmaier, MD; and Loren Walensky, MD, PhD – have received grant awards from the St. Baldrick’s
Foundation this year. The seven grants, which together total more than $1.6 million, will support various pediatric oncology projects ranging from identifying new drug targets and conducting pre-clinical testing of promising agents to studying long-term
May – July 2017
U.S. News & World Report has ranked
Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #2 pediatric cancer program in its new 2017-18 Best Children's Hospitals report.
Dana-Farber has been named to Becker’s Hospital Review’s 2017 list of 100 Great Hospitals in America. The hospitals on the list are recognized for having a strong history of innovation, providing superior care to patients, and leading clinical advancement
with cutting-edge research.
A $4.6 million grant from the Massachusetts Life Sciences Center (MLSC) will help subsidize Dana-Farber’s massive expansion of its advanced facility for developing and making cell therapies to treat cancer and other diseases. The project will make the
Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF) one of the largest
academic centers for manufacturing therapies that rely on modifying cells under highly controlled conditions.
Irene Ghobrial, MD, director of Dana-Farber’s Michele and Stephen Kirsch Laboratory, has received the 2017 Ken Anderson Award from the International Myeloma Society for her research in multiple myeloma. The
award, which honors the contributions of Ken Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma at Dana-Farber,
is given to a scientist under age 45 to recognize and stimulate excellence in myeloma research.
Michael Goldberg, PhD, assistant professor of Cancer Immunology and Virology at Dana-Farber,
is one of nine recipients of Harvard Medical School’s (HMS) 2017 Dean’s Community Service Awards. The award, established in 1999, recognizes individuals who have made outstanding personal efforts in serving the local, national, or international community.
Goldberg received the honor for his work with Camp Casco, a free weeklong summer camp for pediatric cancer patients and survivors.
Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology and scientific director of the Belfer Center for Applied Cancer Science,
is one of two investigators from the National Comprehensive Cancer Network Member Institutions to receive a grant through a collaborative scientific research relationship with AstraZeneca to further evaluate the clinical effectiveness of osimertinib
in the treatment of epidermal growth factor receptor-positive (EGFRm+) non-small cell lung cancer (NSCLC).
Paul G. Richardson, MD, received the prestigious 15th annual Robert A. Kyle Lifetime Achievement Award for advances in research, treatment, and care of multiple myeloma patients. The award, named for renowned
myeloma pioneer Robert Kyle, MD, was presented at a ceremony during the organization’s annual International Myeloma Working Group Summit in Madrid.
Gordon Freeman, PhD, Dana-Farber molecular biologist and immunologist, has been awarded the 2017 Warren Alpert Foundation Prize for transformative discoveries in the field of cancer immunology. Freeman
and four other scientists are sharing the $500,000 prize, given in association with Harvard Medical School (HMS), that recognizes “seminal discoveries that hold the promise to change our understanding of disease or our ability to treat it.”
Laurie H. Glimcher, MD, Dana-Farber President and CEO, is ninth in this year’s ranking of the 50 Most Influential Physician Executives and Leaders compiled by Modern Healthcare, a leading provider of
news and information on the health care industry.
Holcombe Grier, MD, of
Pediatric Oncology, received the Distinguished Career Award from the American Society of Pediatric Hematology/Oncology (ASPHO) at its annual
meeting in Montreal.
Rafael Irizarry, PhD, of
Biostatistics and Computational Biology, has won the 2017 Benjamin Franklin Award for Open Access in the Life Sciences.
The award, presented by bioinformatics.org, an online community of biostatisticians and computational biologists, recognizes an individual who has, in his or her practice, promoted free and open access to the materials and methods used in the life
Pasi A. Jänne, MD, PhD, director of the
Lowe Center for Thoracic Oncology and scientific director of the
Belfer Center for Applied Cancer Science, has been awarded a five-year renewable Clinical Research Professorship
from the American Cancer Society. The grant will support his work in integrating laboratory and clinical research to develop and evaluate new combinations of therapies for genetically distinct subtypes of lung cancer.
Stuart H. Orkin, MD, a researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, whose accomplishments have been recognized with a major German prize and membership in an historic American
society, was elected to the American Philosophical Society (APS), which was founded by Benjamin Franklin in 1743 and was the nation’s first learned society. Orkin was also honored at one of Germany’s oldest and most renowned universities with the
2017 Clotten Foundation Prize for unique contributions to the understanding and treatment of cancer with a particular emphasis on children.
Michael Reney, Dana-Farber senior vice president for finance and chief financial officer (CFO), is listed among 150 Hospital and Health System CFOs to Know by the industry publication Becker’s Hospital Review.
Matthew Meyerson, MD, PhD, and
Ramesh Shivdasani, MD, PhD, have been funded by the Neuroendocrine Tumor Research Foundation as part of a $4 million collaborative grant program. The projects are focusing on how and why neuroendocrine
cells, which are found throughout the body, become cancerous and form carcinoid, pancreatic, and related neuroendocrine cancers.
Justin Brown, PhD, a research fellow in Population Sciences and Gastrointestinal Oncology at Dana-Farber, has received the inaugural National Institutes of Health (NIH) Early-Stage Investigator Award. The award recognizes early-career prevention scientists
who have not competed successfully for a substantial NIH-supported research project before the award nomination submission deadline, but who have already made significant, outstanding research contributions to their respective fields and are poised
to become future leaders in prevention research.
Judy Garber, MD, received the Joseph H. Burchenal Memorial Award, presented for outstanding achievement in clinical cancer research at the annual meeting of the American Association for Cancer Research (AACR).
The award is named for the late Joseph H. Burchenal, MD, a pioneer in the development of chemotherapeutics for the treatment of cancer.
Pasi A. Jänne, MD, PhD, scientific director of the Belfer Center for Applied Cancer Science and director of the Lowe Center for Thoracic Oncology, and Alice Shaw, MD, PhD, director of the Center for Thoracic Cancers at Massachusetts General Hospital,
have been named co-leaders of the Stand Up To Cancer–American Cancer Society Lung Cancer Dream Team.
Eric Winer, MD, of the
Susan F. Smith Center for Women’s Cancers at Dana-Farber, received the 2017 Gianni Bonadonna Breast Cancer Award which recognizes his significant contributions and active clinical and translational
breast cancer research. Dr. Winer has advanced science, improved clinical care and is mentoring the next generation of breast cancer researchers and clinicians.
Three Dana-Farber physicians have been chosen as part of the 2017 class of new members of the American Society for Clinical Investigation (ASCI). They are
Adam Bass, MD, of the
Gastrointestinal Cancer Center;
Rameen Beroukhim, MD, PhD, of the
Center for Neuro-Oncology, and W. Nicholas Haining, MD, BCh, of
Four Dana-Farber scientists have received Outstanding Investigator Awards from the National Cancer Institute (NCI), providing seven years of support for new projects “of unusual potential.” The recipients are
William Kaelin, MD, of
A. Thomas Look, MD, and
Kimberly Stegmaier, MD, of Pediatric Oncology; and
Jean Zhao, PhD, of
Cancer Biology. The awards, which provide up to $600,000 per year in direct costs, were developed in 2014 to give investigators more time than
standard grants allow to break new ground or extend previous discoveries to advance biomedical, behavioral, or clinical cancer research..
Three Dana-Farber physician-scientists have been named to a Stand Up To Cancer (SU2C) Colorectal Cancer Dream Team under a $12 million translational research grant awarded to six institutions in the United States. They are Marios Giannakis, MD, PhD,
the principal investigator of the grant at Dana-Farber; and Nick Haining, BM, BCh, and
Natalie Collins, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
February – April 2017
Daphne Haas-Kogan, MD, of Dana-Farber's
Department of Radiation Oncology, was elected a member of the Association of American Physicians (AAP). The AAP is a nonprofit, professional
organization composed of members who are leading senior physician scientists and are competitively selected on an annual basis.
Marsha Joselow, LICSW, MSW, was awarded the 2017 Social Work Hospice and Palliative Care Network Award for Excellence in Professional Education.
Ji Li, PhD, and
Heather Parsons, MD, MPH, of Dana-Farber's
Department of Medical Oncology, have been selected as 2017 grant recipients from the Terri Brodeur Breast Cancer Foundation.
Geoffrey Shapiro, MD, PhD, and
Jean Zhao, PhD, are the first recipients of a new program project grant in breast and gynecologic cancer research sponsored by the
Susan F. Smith Center for Women's Cancers. The grant of $500,000 annually for three years is intended to foster research in both
breast and gynecologic malignancies - particularly studies that could potentially lead to clinical trials.
Michael Goldberg, PhD, of Dana-Farber's
Department of Cancer Immunology and Virology, has won a two-year early career award from the Ovarian Cancer Research Fund Alliance
(OCRFA) to study potential immunotherapy strategies for treating ovarian cancer.
Eric Zhou, PhD, is one of four researchers selected to receive a psychosocial grant from Alex’s Lemonade Stand Foundation (ALSF). Awardees of the Psychosocial Launch Grant, designed for early career researchers
whose studies aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer, will receive up to $100,00 over two years.
November 2016 – January 2017
Pediatric Palliative Care Research Network, a multi-center
team of researchers and clinicians working to improve palliative care for children and their families, received a $2 million grant from the National Institute of Nursing Research, which will fund a new cohort study looking at palliative care outcomes
for 800 children over the span of two years.
Boston magazine has named 51 physicians and surgeons affiliated with Dana-Farber to its annual Top Doctors Guide. Drawing from a Castle Connolly Medical Ltd. Physician database, the list consists of over 600 Boston area physicians from more than
60 medical specialties and is available on Boston magazine’s website.
Loren Walensky, MD, PhD, faculty member in Dana-Farber's Department of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, and director of the Harvard/MIT MD-PhD program, has been promoted
to professor at Harvard Medical School.
Edward J. Benz Jr., MD, Dana-Farber president emeritus, has received a 2016 SPARK! Award from the Albert Schweitzer Fellowship for his leadership in calling attention to and reducing racial disparities
in cancer care. He was also honored for his leadership in broadening access to high quality cancer care, locally and around the world. He received the first Global Oncology Visionary Award from Global Oncology (GO), a nonprofit committed to reducing
disparities in access to cancer care.
George P. Canellos, MD, received the Robert Kyle Award from the Mayo Clinic for his career contributions to hematologic disease, specifically malignant lymphoma. Canellos also received the John Ultmann
Award at the Lymphoma & Myeloma 2016 meeting in October in New York City.
Gordon Freeman, PhD, of
Medical Oncology, has been named a 2016 Thomson Reuters Citation Laureate for the field of medicine, along with his wife and colleague, Arlene
Sharpe, MD, PhD, of Harvard Medical School and Brigham and Women’s Hospital, and Tasuku Honjo, MD, PhD, of Kyoto University, in Japan. The honor, given by Clarivate Analytics, a computer analysis company, recognizes researchers whose advances are
among the most cited in their field.
Laurie H. Glimcher, MD, president and CEO of Dana-Farber, received the Marion Spencer Fay Award from the Institute for Women’s Health and Leadership at Drexel University in Philadelphia. Given annually,
this award is presented to a woman physician or scientist who has made significant contributions to health care as a practitioner, medical educator, administrator, or research scientist. The award, which includes a $10,000 honorarium, was created
to honor Marion Spencer Fay, a former dean and president of the Women’s Medical College of Pennsylvania.
Charlotta Lindvall, MD, PhD, of
Adult Palliative Care, is one of five winners of an Innovation Challenge issued by the National Quality Forum (NQF), which aims to introduce novel methods to improving quality measurement in health care. Lindvall’s
project, for which she is partnering with surgeons at Brigham and Women’s Hospital and researchers at Massachusetts Institute of Technology, focuses on improving care for palliative surgery patients using natural language processing to mine the electronic
medical record. Lindvall and the other winners will be part of NQF’s first Measure Incubator™ Learning Collaborative, which will connect them with experts, resources, and data to implement their measures nationally.
Ursula Matulonis, MD,has been promoted to professor of Medicine at Harvard Medical School. Matulonis is medical director and program leader of
Gynecologic Oncology at Dana-Farber, interim director of the Susan F. Smith Center for Women's Cancers, and institute physician.
Dana-Farber President Emeritus
David G. Nathan, MD, has been selected for the 2016 Andover Alumni Award of Distinction by the Alumni Council of Phillips Academy.
David Reardon, MD, has been promoted to professor of Medicine at Harvard Medical School. Reardon earned his medical degree from Tufts University School of Medicine, followed by residency and fellowship at
Johns Hopkins Hospital and the University of Michigan.
Timothy R. Rebbeck, PhD, will receive the Joseph F. Fraumeni Jr. Distinguished Achievement Award from the American Society for Preventive Oncology at its 2017 annual meeting.
Deborah Schrag, MD, chief of Dana-Farber's
Division of Population Sciences in Medical Oncology, is the 2016 recipient of the Richard L. Schilsky Cancer and Leukemia
Group B Achievement Award presented by the Alliance for Clinical Trials in Oncology. Established in 2010, the award acknowledges the significant contributions of an individual to cooperative group research.
Steven P. Treon, MD, PhD, has been promoted to professor of Medicine at Harvard Medical School.
Eric Wang, PhD, of Cancer Biology, has received a fellowship grant from the Damon Runyon Cancer Research Foundation, which supports the work of innovative early career researchers across the country. The four-year award will support work by Wang and his
sponsor, Nathanael Gray, PhD, to use chemical biology techniques to identify enzymes and small-molecule inhibitors that enhance the immune system’s ability to detect and destroy emerging tumors.
Susan A. Wills, MBA, CMRP, director of strategic sourcing and contracts at Dana-Farber, earned Fellow status in the Association for Healthcare Resource and Materials Management.
St. Baldrick’s Foundation has awarded more than $1.7 million in grants to scientists at
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to support research in pediatric cancers. The foundation, a charity that raises money for childhood cancer research,
also awarded three consortium grants totaling nearly $1.5 million to Dana-Farber/ Boston Children’s investigators:
- Christine Duncan, MD, and her team will be supported with $499,605 in funding for research to better understand, prevent, and treat late, organ-specific effects of childhood cancer bone marrow transplantation
in an effort to improve long-term survival.
- Lindsay Frazier, MD, received a grant of $496,614 to lead the Malignant Germ Cell International Consortium (MaGIC) that she created. It is the first multinational consortium addressing this disease,
which is the most common solid tumor in adolescents and young adults. This group includes not only pediatric oncologists, but also the world’s leaders in germ cell tumors from adult oncology, gynecologic, and genitourinary oncology. MaGIC has
already launched three new joint international NCI-funded clinical trials, is evaluating a new diagnostic test that appears to be nearly 100 percent sensitive in detecting relapse, and is investigating the underlying biological causes of this
- Kimberly Stegmaier, MD, will use her grant of $500,000 for research in leukemia, including the first multi-institutional genomics-based precision medicine trial for children with relapsed or very high-risk
leukemias. New technologies will be deployed to sequence all currently known cancer-promoting genes in an individual child’s leukemia. Then, guided by a multidisciplinary group of leukemia experts, treatment recommendations will be made based
upon the genomic findings in the individual child’s leukemia and the availability of a relevant targeted drug for children.
- Rameen Beroukhim, MD, PhD, received a $100,000 grant to study mutations that enable incurable pediatric brain tumors called diffuse intrinsic pontine gliomas (DIPG) to resist current treatments. The funding
will allow Beroukhim and his colleagues to evaluate DIPG specimens from children and determine how the tumors are able to evade treatment, so that more effective treatment strategies can be devised.
- Brian Crompton, MD, was named the “Team Clarkie Fund St. Baldrick’s Scholar,” which provides $75,000 to validate a new targeted therapy approach for Ewing sarcoma, an aggressive bone tumor in adolescents
and young adults. Crompton is also developing a new screening effort to identify additional drug targets in Ewing sarcoma.
- Michael Eck, MD, PhD, received a $100,000 “For the Love of Jack St. Baldrick’s Research Grant” to find new targeted therapies for low-grade astrocytoma brain tumors that are caused by mutations in a protein
called BRAF. The research is intended to develop a detailed understanding of a particular BRAF mutation with the aim of discovering drugs to target this mutation.
August – October 2016
Dana-Farber/Brigham and Women’s Cancer Center has been named the best for cancer care in New England for the 16th straight year, and fourth overall in the country by U.S. News & World Report.
Dana-Farber Cancer Institute has been named to Becker’s Hospital Review’s 2016 list of 100 Great Hospitals in America. The hospitals on the list are recognized for having a strong history of innovation, providing superior care to patients, and leading
clinical advancement with cutting-edge research.
A team led by
Gregory Abel, MD, MPH, a member of the
Division of Population Sciences and the
Division of Hematologic Malignancies at Dana-Farber, has been selected to receive $2.6 million funding from the Patient-Centered Outcomes Research Institute for a five-year clinical trial to determine
if a Shared Care program can be effective in providing quality follow-up care for transplant patients.
Rameen Beroukhim, MD, PhD, received a $100,000 grant from St. Baldrick’s Foundation to study mutations that enable incurable pediatric brain tumors called diffuse intrinsic pontine gliomas to resist current
Brian Crompton, MD, was named the “Team Clarkie Fund St. Baldrick’s Scholar,” which provides $75,000 to validate a new targeted therapy approach for Ewing sarcoma, an aggressive bone tumor in adolescents
and young adults.
Christine Duncan, MD, and her team will be supported with $499,605 in funding from St. Baldrick’s Foundation for research to better understand, prevent, and treat late organ-specific effects of childhood
cancer bone marrow transplantation in an effort to improve long-term survival.
Michael Eck, MD, PhD, received a $100,000 “For the Love of Jack St. Baldrick’s Research Grant” to find new targeted therapies for low-grade astrocytoma brain tumors that are caused by mutations in a protein
called BRAF. The research is intended to develop a detailed understanding of a particular BRAF mutation with the aim of discovering drugs to target this mutation.
Mariella G. Filbin, MD, PhD, a pediatric neuro-oncologist, has won a Burroughs Wellcome Fund Career Award for Medical Scientists. She is among 12 physician-scientists selected for the awards, which provide $700,000 over five years to bridge advanced postdoctoral
or fellowship training and the early years of faculty service.
Lindsay Frazier, MD, received a grant of $496,614 from St. Baldrick’s Foundation to lead a consortium she has created, the Malignant Germ Cell International Consortium. The Consortium is the first multinational
consortium addressing this disease, which is the most common solid tumor in adolescents and young adults.
Laurie H. Glimcher, MD, Dana-Farber’s President and CEO, received the Institute for Women's Health and Leadership's Marion Spencer Fay Award. The national Marion Spencer Fay Award is given annually to
a woman physician or scientist who has made an exceptionally significant contribution to health care as a practitioner, medical educator, administrator or research scientist. The award includes a $10,000 honorarium.
Stephen Hodi, MD, has been promoted to professor of Medicine at Harvard Medical School
William G. Kaelin, MD, Dana-Farber physician-scientist, has been named a winner of the 2016 Lasker Award along with two other scientists for groundbreaking basic research on how the body senses and
adapts to changes in oxygen availability.
Matthew Kulke, MD, has been promoted to professor of Medicine at Harvard Medical School.
Joshua Lakin, MD, of Dana-Farber/Brigham and Women’s Cancer Center, received the Cambia Health Foundation’s two-year, $180,000 grant through the Sojourns Scholar Leadership Program. The Sojourns Scholar
Leadership Program is an initiative designed to advance the next generation of palliative care leaders.
Ann Mullally, MD, of Hematologic Oncology received a research awards from the Damon Runyon Cancer Research Foundation. Mullally’s award was a Continuation Grant for her Damon Runyon Clinical Investigatorship.
Continuation grants, which provide $300,000 over two years, support Runyon clinical investigators who are approaching the end of their original awards and need extra time and funding to complete a promising avenue of research or initiate or continue
a clinical trial developing next generation assays for biological changes in tumors and tracking the emergence of drug resistance.
Geoffrey Oxnard, MD, of Dana-Farber's
Thoracic Oncology Program, recently received a Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Established in 2009, the awards support outstanding mid-career
clinical investigators at NCI-designated cancer centers who have extensive involvement in NCI-funded collaborative clinical trials and whose leadership and example promote clinical trials and research. He also received a research award from the Damon
Runyon Cancer Research Foundation. As a Damon Runyon Clinical Investigator, Oxnard will receive $450,000 over three years to support his research. The investigatorships are awarded to outstanding early career physician-scientists working under the
mentorship of leading scientists and clinicians across the country.
Michael Reney, Dana-Farber’s chief financial officer (CFO), was named to Becker’s Hospital Review’s 2016 “150 Hospital and Health
System CFOs to Know” list. The annual list features financial executives from for- and nonprofit hospitals and health systems across the country, highlighting the men and women who help their organizations navigate the challenging changes in health
Justin Sanders, MD, MSc, of Dana-Farber/Brigham and Women’s Cancer Center, received the Cambia Health Foundation’s two-year, $180,000 grant through the Sojourns Scholar Leadership Program. The Sojourns
Scholar Leadership Program is an initiative designed to advance the next generation of palliative care leaders.
Alexander Spektor, MD, PhD, radiation oncologist, has won a Burroughs Wellcome Fund Career Award for Medical Scientists. He is among 12 physician-scientists selected for the awards, which provide $700,000
over five years to bridge advanced postdoctoral or fellowship training and the early years of faculty service.
Kimberly Stegmaier, MD, received a grant of $500,000 from St. Baldrick’s Foundation for research in leukemia, including the first multi-institutional genomics-based precision medicine trial for children
with relapsed or very high-risk leukemias.
Eric Wang, PhD, of
Cancer Biology, has received a fellowship grant from the Damon Runyon Cancer Research Foundation, which supports the work of innovative early-career
researchers across the country. The four-year award will support work by Wang and his sponsor, Nathanael Gray, PhD, to use chemical biology techniques to identify enzymes and small-molecule inhibitors that enhance the immune system’s ability to detect
and destroy emerging tumors.
May – July 2016
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is the nation’s #1 pediatric cancer program, according to the U.S. News & World Report’s 2016-17 Best Children’s
Hospitals rankings. This marks the third year in a row that Dana-Farber/Boston Children’s topped U.S. News’s pediatric cancer rankings. Boston Children’s Hospital remained the best pediatric hospital in the country.
The Harris Poll© ranked the
Jimmy Fund one of the nation's top five strongest brands in the Health Nonprofit category in its 28th annual EquiTrend Study.
Adam Bass, MD, and Charles S. Fuchs, MD, MPH, were honored at the American Cancer Society’s annual Financial Services Cares Gala in New York. Fuchs, director of Dana-Farber’s
Gastrointestinal Cancer Center, and Bass, a physician-scientist at Dana-Farber who does research in stomach cancer and is an associate member of the Broad Institute of MIT and Harvard, received
the Eugene D. O’Kelly Award.
Edward J. Benz Jr., MD, has been selected as a 2016 Innovator in Health by the Network for Excellence in Health Innovation for “his extraordinary innovation in the field of cancer medicine, leadership
in the Boston health care community, and commitment to collaborative care.” He was also named to Massachusetts General Hospital Cancer Center’s “the one hundred.”
Judy E. Garber, MD, MPH, director of Dana-Farber’s
Center for Cancer Genetics and Prevention, has been appointed chair of the Scientific Advisory Board of the Breast Cancer Research Foundation, effective June 1.
William G. Kaelin Jr., MD, has received the 10th annual Princess Takamatsu Award from the American Association for Cancer Research. He also was honored with the ASCO Science of Oncology Award and gave
a lecture discussing new cancer treatments emerging from studies of the VHL tumor suppressor protein and IDH oncoproteins.
Franziska Michor, PhD, received the award for Outstanding Achievement in Cancer Research at the 2016 American Association for Cancer Research Annual Meeting in New Orleans. The award is given to an investigator
younger than 40.
Francesca Noll, RT(T), has been named to Massachusetts General Hospital Cancer Center's "the one hundred."
Kimberly Stegmaier, MD, has been awarded a research grant from The Rally Foundation for Childhood Cancer Research to investigate new potential drug targets in acute lymphoblastic leukemia.
Joanne Wolfe, MD, MPH, division chief of
Pediatric Palliative Care at Dana-Farber and director of Palliative Care at Boston Children’s Hospital, delivered the 2016 Frank A. Oski Lecture at the American Society of Pediatric Hematology/Oncology
annual meeting. The lectureship is awarded annually to an outstanding clinical or laboratory investigator in pediatric hematology/oncology.
September 2015 – April 2016
The Schwartz Center for Compassionate Healthcare recognized Dana-Farber for hosting the Schwartz Center Rounds for more than 10 years.
The Association for the Accreditation of Human Research Protection Programs Inc. has awarded Dana-Farber, on behalf of Dana-Farber/Harvard Cancer Center (DF/HCC), a full five-year reaccreditation.
The Joint Commission concluded a five-day, 90-hour hospital survey. Three surveyors from the Joint Commission lauded Dana-Farber’s care as “the way it’s supposed to be.” They documented excellence at every level, and identified only a few areas for improvement.
Dana-Farber was ranked fourth in the country in NurseJournal.org’s Top 100 Most Social Media Friendly Hospitals for 2014 for having a strong social media presence on Facebook and Twitter.
Dana-Farber has been recognized as a Leader in LGBT Healthcare Equality by the Human Rights Campaign Foundation as a result of its findings from the Healthcare Equality Index 2016, an annual survey that encourages equal care by evaluating inclusive policies
and practices related to LGBT patients, visitors, and employees.
Dana-Farber received an award for greatest electricity reduction in 2015 in Better City’s Seventh Annual Challenge for Sustainability Awards.
Boston magazine has named 60 physicians and surgeons affiliated with Dana-Farber to its annual Top Doctors guide.
Myles Brown, MD, has been elected to the National Academy of Sciences. Brown, who is the director of the
Center for Functional Cancer Epigenetics at Dana-Farber, is one of 84 new members and 21 foreign associates from 14 countries
elected to the Academy in recognition of their distinguished and continuing achievements in original research.
Paul Richardson, MD, clinical program leader and director of clinical research at Dana-Farber/Brigham and Women's Cancer Center's
Jerome Lipper Center for Multiple Myeloma, and RJ Corman Professor of Medicine at Harvard Medical School, received the Multiple Myeloma Achievement Award at
the 2nd World Congress on Controversies in Multiple Myeloma, held in Paris.
Matthew Meyerson, MD, PhD, has received the 2016 Han-Mo Koo Memorial Award from the Van Andel Research Institute (VARI). The award recognizes Meyerson's "immeasurable contributions to the understanding
of cancer genomics and targeted therapies."
Fatih Aydogan, MD, FEBS, a postdoctoral research fellow in the
Susan F. Smith Center for Women's Cancers at Dana-Farber, received the 2015 Conquer Cancer Foundation of the American Society of Clinical Oncology Merit Award. This honor recognizes early-career
oncologists and scientists for their significant research accomplishments.
Amanda Balboni, PhD, and Neil T. Umbreit, PhD, were named Damon Runyon Fellows by the Damon Runyon Cancer Research Foundation at the 2015 Fellowship Award Committee meeting. Fellows are outstanding postdoctoral scientists involved in cancer research in
the labs of leading senior investigators.
The Visiting Nurse Association of Boston honored Dana-Farber President and CEO
Edward J. Benz Jr., MD, as a 2015 Hero in Health Care for leading the Institute’s transformation during his 15-year tenure.
Rachelle E. Bernacki, MD, MS, director of Quality Initiatives in the Division of
Adult Palliative Care, Department of Psychosocial Oncology and Palliative Care, received the Cambia Health Foundation’s two-year, $180,000 grant through the Sojourns Scholar Leadership Program. The grant provides
educational and leadership development opportunities.
Myles Brown, MD; David Livingston, ND;
Ann Partridge, MD, MPH; Remigio Picone, PhD;
Nikhil Wagle, MD;
Eric Winer, MD, will receive a total of $2.28 million in new grants for basic and clinical studies of breast cancer from Susan G. Komen®.
Myles Brown, MD, received the Susan G. Komen® Brinker Award for Scientific Distinction in Basic Science. Established in 1992, the award recognizes the efforts of pioneers in two critically important areas of the fight to end breast cancer: clinical research
and basic science.
Ennio A. Chiocca, MD,PhD, has been elected president of the Society for Neuro-Oncology, an organization representing North American neuro-oncologists and scientists.
Anthony D’Amico, MD, PhD, chief of Genitourinary
Radiation Oncology and an Institute Physician at Dana-Farber, received the Kligerman Award for radiation oncology research from the Perelman School of Medicine at the University of Pennsylvania.
The Association of Pediatric Hematology/Oncology Nurses recently honored Jimmy Fund Clinic nurse Denise Desrochers, RN, CPON, with the Certified Pediatric Oncology Nurse (CPON) of the Year Award. The award recognizes a CPON who has made significant contributions
to pediatric oncology or hematology nursing and who has supported and promoted oncology nursing certification.
Levi Garraway, MD, PhD; Matthew Meyerson, MD, PhD;
Shuji Ogino, MD, PhD;
Kornelia Polyak, MD; and
Loren Walensky, MD, PhD, are among the first group of scientists to receive Outstanding Investigator Awards from the National Cancer Institute. The awards were created last year to provide funding to
cancer scientists with outstanding records of productivity to continue or embark on new projects of unusual potential over an extended period of seven years.
The Li-Fraumeni Syndrome (LFS) Association honored Dana-Farber’s
Judy Garber, MD,MPH, and Katherine Schneider, MPH, LGC, with “Hero” awards for their uncompromised dedication to LFS treatment and research.
Krietta Bowens Jones, associate general counsel at Dana-Farber, has been appointed to a two-year term as co-chair of the Delivery of Legal Services section of the Boston Bar Association.
Shirley Liu, PhD, director of the Center for Functional Cancer Epigenetics at Dana-Farber, and professor of biostatistics and computational biology at the Harvard T.H. Chan School of Public Health, has received the Richard W. Weitzman Outstanding Early
Career Investigator award for her work in the computational modeling of transcriptional and epigenetic gene regulation.
Jessica Lord, benefits compliance and operations manager in Human Resources, won a Rising Star Award at the 2015 New England Employee Benefits Council’s 17th Annual Best Practices Conference. The award recognizes new benefits professionals who have demonstrated
exceptional promise in their field.
The National Institutes of Health is funding collaborative research by Dana-Farber and a biotech company to improve the performance of an invention by
Mike Makrigiorgos, PhD, of Radiation Oncology. Dana-Farber and Transgenomic will be partners under the two-year, $1.5 million NIH Small Business Technology Transfer grant.
Mary McKenney, MSN, NP, was recognized as a CURE Magazine Extraordinary Healer.
Fremonta Meyer, MD, was awarded the Jonathan F. Borus Outstanding Early Career Educator Award in medical student education for 2015. Meyer received the award for her outstanding work and commitment to her
psychiatry students at Dana-Farber and Brigham and Women’s Hospital.
Matthew Meyerson, MD, PhD, was honored as a 2015 Biomedical Research Leader at the annual Biomedical Research Day Honors Luncheon of the Massachusetts Society for Biomedical Research. Meyerson received the honor for his contributions to biomedical research
and education in New England.
Wilfred Ngwa, PhD, of Radiation Oncology, has been awarded a $100,000 Bright Futures Prize to support the development of miniature programmable drone-like particles to fight metastatic cancer.
The Patient-Centered Outcomes Research Institute has given investigators at Dana-Farber and allied institutions a $13.3 million funding award to study treatment options for patients with ductal carcinoma in situ. Ann Partridge, MD, MPH, a senior physician
in the Susan F. Smith Center for Women’s Cancers at Dana-Farber, is the study’s co-principal investigator.
Kornelia Polyak, MD, PhD, of Medical Oncology, received the 14th Rosalind E. Franklin Award for Women in Science at the Annual National Cancer Institute Intramural Scientific Retreat. The award, which honors Franklin’s role in the discovery of the DNA
double helix, recognizes the commitment of women in cancer research.
The American Nurses Association Board of Directors has appointed
Patricia Reid Ponte, DNSc,RN, NEA-BC, FAAN, president of the American Nurses Credentialing Center.
Dorothy Puhy, Dana-Farber’s executive vice president and chief operating officer, was honored by the Boston Business Journal’s 2015 WomenUp: Local Women of Influence program. The program recognizes women who have made a difference in their businesses,
industries, and communities.
Kimberly Stegmaier, MD, of
Dana-Farber/Boston Children’s Cancer and Blood DisordersCenter, will receive the 2016 E. Mead Johnson Award in Pediatric Research for her work in discovering new molecular targets
in several childhood cancers and bringing potential treatments to clinical trials. The award, given since 1939 by the Society for Pediatric Research, is conferred on two scientists each year.
Susan Block, MD, an Institute physician in Dana-Farber's
Department of Psychosocial Oncology and Palliative Care, Harvard Medical School professor, and director of the Serious
Illness Care Program at Ariadne Labs, has received the Lifetime Achievement Award at the American Academy of Hospice and Palliative Medicine (AAHPM) Annual Assembly in Chicago. The award is among the highest honors in the field.